Literature DB >> 30980231

Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion.

Tomoharu Nishimura1, Shigeki Machida2, Atsushi Tada1, Eiki Oshida1, Tetsuya Muto1.   

Abstract

PURPOSE: To determine the physiology of the macula by the focal macular electroretinograms (fmERGs) in patients with branch retinal vein occlusion with macular edema (BRVOME) treated by intravitreal injections of ranibizumab (IVR).
METHODS: We studied 17 eyes of 17 patients with BRVOME. The contralateral unaffected eyes served as controls. All patients were treated with an IVR at monthly intervals for 3 consecutive months. The baseline best-corrected visual acuity (BCVA), optical coherence tomographic (OCT) findings, and fmERGs were compared to the post-treatment values. The fmERGs were elicited by a 15° circular spot or a superior or inferior semicircular spot. The center of the spot was placed on the fovea. The amplitudes of the a- and b-waves, photopic negative response (PhNR), and sum of the oscillatory potentials (ΣOPs: sum of OP1, OP2, and OP3 amplitudes) were measured. In addition, the implicit times of the a- and b-waves were also measured.
RESULTS: The BCVA improved significantly from 0.39 ± 0.28 logMAR units to 0.17 ± 0.18 logMAR units after the resolution of the central macular edema (P < 0.01). All components of the fmERGs elicited by the semicircular stimulus spot placed on the occluded side were smaller than that elicited from the corresponding area of the control eyes. The b-wave amplitudes increased significantly from 0.49 ± 0.25 to 0.75 ± 0.36 µV following the IVR injections, but the amplitudes of the a-wave and PhNR remained reduced (P < 0.05). The amplitudes of the PhNR and ΣOPs elicited by stimulating the non-occluded side were reduced with relative preservation of the a- and b-waves (P < 0.05). They recovered after the treatment from 0.27 ± 0.15 to 0.50 ± 0.30 and 0.33 ± 0.15 to 0.53 ± 0.19 µV, respectively.
CONCLUSIONS: IVRs improved the macular function not only on the occluded side but also on the non-occluded side. On the occluded side, the BRVOME affects the function of all retinal layers of the macula. Even after the IVR, the function of the photoreceptors and retinal ganglion cells remained abnormal. On the non-occluded side, the inner retinal function improved after the IVR.

Entities:  

Keywords:  BRVO; Focal macular ERG; Macular edema; Macular function; Ranibizumab

Mesh:

Substances:

Year:  2019        PMID: 30980231     DOI: 10.1007/s10633-019-09696-5

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  20 in total

1.  Recurrence of macular edema in eyes with branch retinal vein occlusion changes the diameter of unaffected retinal vessels.

Authors:  Jong Chan Im; Jae Pil Shin; In Taek Kim; Dong Ho Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-09-18       Impact factor: 3.117

2.  Perimetric sensitivity with the micro perimeter 1 and retinal thickness in patients with branch retinal vein occlusion.

Authors:  Noritatsu Yamaike; Mihori Kita; Akitaka Tsujikawa; Kazuaki Miyamoto; Nagahisa Yoshimura
Journal:  Am J Ophthalmol       Date:  2006-10-17       Impact factor: 5.258

3.  Nine-year incidence and risk factors for retinal vein occlusion in a general Japanese population: the Hisayama Study.

Authors:  Satoshi Arakawa; Miho Yasuda; Masaharu Nagata; Toshiharu Ninomiya; Yoichiro Hirakawa; Yasufumi Doi; Yutaka Kiyohara; Tatsuro Ishibashi
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-29       Impact factor: 4.799

4.  Changes of oscillatory potentials and photopic negative response in patients with early diabetic retinopathy.

Authors:  Junya Kizawa; Shigeki Machida; Takaki Kobayashi; Yasutaka Gotoh; Daijiro Kurosaka
Journal:  Jpn J Ophthalmol       Date:  2006 Jul-Aug       Impact factor: 2.447

5.  Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

Authors:  Peter A Campochiaro; Jeffrey S Heier; Leonard Feiner; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Wendy Yee Murahashi; Roman G Rubio
Journal:  Ophthalmology       Date:  2010-04-15       Impact factor: 12.079

6.  Recording focal macular photopic negative response (PhNR) from monkeys.

Authors:  Mineo Kondo; Yukihide Kurimoto; Takao Sakai; Toshiyuki Koyasu; Kentaro Miyata; Shinji Ueno; Hiroko Terasaki
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-25       Impact factor: 4.799

7.  Asymmetry of focal ERG in human macular region.

Authors:  Y Miyake; N Shiroyama; M Horiguchi; I Ota
Journal:  Invest Ophthalmol Vis Sci       Date:  1989-08       Impact factor: 4.799

8.  Quantitative Optical Coherence Tomography Angiography Features and Visual Function in Eyes With Branch Retinal Vein Occlusion.

Authors:  Wasim A Samara; Abtin Shahlaee; Jayanth Sridhar; M Ali Khan; Allen C Ho; Jason Hsu
Journal:  Am J Ophthalmol       Date:  2016-03-31       Impact factor: 5.258

9.  Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.

Authors:  W Lloyd Clark; David S Boyer; Jeffrey S Heier; David M Brown; Julia A Haller; Robert Vitti; Husain Kazmi; Alyson J Berliner; Kristine Erickson; Karen W Chu; Yuhwen Soo; Yenchieh Cheng; Peter A Campochiaro
Journal:  Ophthalmology       Date:  2015-10-30       Impact factor: 12.079

10.  Analysis of Potential Ischemic Effect of Intravitreal Bevacizumab on Unaffected Retina in Treatment-Naïve Macular Edema Due to Branch Retinal Vein Occlusion: A Prospective, Interventional Case-Series.

Authors:  Pukhraj Rishi; Neha Raka; Ekta Rishi
Journal:  PLoS One       Date:  2016-09-12       Impact factor: 3.240

View more
  2 in total

1.  Efficacy of intravitreal Lucentis injection on major and macular branch retinal vein occlusion.

Authors:  Jing Wang; Ying Li; Shu-Fen Fang; Hong Wang
Journal:  BMC Ophthalmol       Date:  2020-07-09       Impact factor: 2.209

Review 2.  Clinical electrophysiology of the optic nerve and retinal ganglion cells.

Authors:  Oliver R Marmoy; Suresh Viswanathan
Journal:  Eye (Lond)       Date:  2021-06-11       Impact factor: 3.775

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.